Javascript must be enabled to continue!
Multiple‐Dose Pharmacokinetics of Nilvadipine in Healthy Volunteers
View through CrossRef
Nilvadipine, a new antihypertensive and antianginal drug, was studied in six healthy male volunteers to evaluate its steady‐state pharmacokinetics after oral dosing. The subjects were given a single dose of 4 mg, followed by 4 mg every 12 hours for six days after a washout period of more than 3 days. The pharmacokinetics of nilvadipine were well described by a linear model of triexponential equation with zero‐order absorption. The steady state was reached by the fourth day of multiple dosing, with a twofold accumulation of trough plasma concentration and no accumulation of peak concentration. The mean plasma concentration at steady state was 1.0 ng/mL. The optical enantiomers of nilvadipine were also determined in the plasma. The plasma concentration of (+)‐nilvadipine was about two and a half times higher than that of (‐)‐nilvadipine, and this ratio was unaffected by multiple dosing.
Title: Multiple‐Dose Pharmacokinetics of Nilvadipine in Healthy Volunteers
Description:
Nilvadipine, a new antihypertensive and antianginal drug, was studied in six healthy male volunteers to evaluate its steady‐state pharmacokinetics after oral dosing.
The subjects were given a single dose of 4 mg, followed by 4 mg every 12 hours for six days after a washout period of more than 3 days.
The pharmacokinetics of nilvadipine were well described by a linear model of triexponential equation with zero‐order absorption.
The steady state was reached by the fourth day of multiple dosing, with a twofold accumulation of trough plasma concentration and no accumulation of peak concentration.
The mean plasma concentration at steady state was 1.
0 ng/mL.
The optical enantiomers of nilvadipine were also determined in the plasma.
The plasma concentration of (+)‐nilvadipine was about two and a half times higher than that of (‐)‐nilvadipine, and this ratio was unaffected by multiple dosing.
Related Results
Pharmacokinetics of Nilvadipine in Healthy Volunteers
Pharmacokinetics of Nilvadipine in Healthy Volunteers
The pharmacokinetics of nilvadipine, a new antihypertensive and antianginal drug, were examined in healthy male volunteers. In a Latin square, three‐way crossover design with a one...
Abstract 2656: Ethical considerations in evaluating targeted anticancer drug candidates in healthy volunteers – safety and risk assessments
Abstract 2656: Ethical considerations in evaluating targeted anticancer drug candidates in healthy volunteers – safety and risk assessments
Abstract
Background: Biopharmaceutical and clinical pharmacology studies are typically conducted in healthy volunteers with few exceptions, such as for anti-cancer d...
Population Pharmacokinetics of Rifampicin on Pulmonary Tuberculosis Patients
Population Pharmacokinetics of Rifampicin on Pulmonary Tuberculosis Patients
Abstract: This study aimed to establish a reasonable population pharmacokinetic model for rifampicin taken orally by patients with pulmonary tuberculosis, estimate pharmacokinetic ...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
10th Annual Meeting, 25‐26 November 1976, Adelaide 1. Histamine metabolism in aortae of two histamine sensitive species. A. Foldes, M. J. Stacey and I. S. de la Lande 2. Localizat...
Nilvadipine attenuates ischemic degradation of gerbil brain cytoskeletal proteins.
Nilvadipine attenuates ischemic degradation of gerbil brain cytoskeletal proteins.
We have previously demonstrated that transient cerebral ischemia induces marked decreases in concentrations of cytoskeletal proteins and have suggested putative involvement of calp...
Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials
Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials
Objectives: This study aimed to investigate the pharmacokinetic characteristics of siponimod in healthy volunteers and patients with MS based on aggregated data from published clin...
Pharmacokinetics and safety of gadopiclenol in Japanese healthy volunteers
Pharmacokinetics and safety of gadopiclenol in Japanese healthy volunteers
Abstract
Purpose
The aim of this study was to evaluate the pharmacokinetics and safety of gadopiclenol in Japanese health...
Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria.
Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria.
The single-dose pharmacokinetics of 100 mg of orally administered artesunate (AS) were studied in 6 patient volunteers with uncomplicated falciparum malaria and in 6 healthy volunt...

